As for TMB in pan-glioma, the high CLCF1 expression subgroup presented higher somatic mutation levels (Supplementary Figure S10C) and higher mutation levels in TP53, ATRX, EGFR, and PTEN, while the low CLCF1 subgroup presented higher mutation level in IDH1 and CIC(Supplementary Figures S10A, B). This evidence concerns the gene TP53 and central nervous system cancer.